Back to today’s briefing

Story perspectives

Erleada-Hormone Combo Slashes Prostate Cancer Spread, Recurrence 20%

5/31/2026

50 6 Full Breakdown

Summary

Story summary

Erleada plus hormone therapy delayed treatment by over six years, nearly double hormone-only.
In a trial of over 2,000 U.S. prostate cancer patients, 9% of combo-treated had little or no detectable cancer at surgery versus 1% with hormone therapy alone.
The regimen cut risk of spread or death by 20% and lowered recurrence risk by 29%.
Johnson & Johnson will seek global approval and said safety matches earlier Erleada studies.

1 of 1

Story summary

Erleada plus hormone therapy delayed treatment by over six years, nearly double hormone-only.
In a trial of over 2,000 U.S. prostate cancer patients, 9% of combo-treated had little or no detectable cancer at surgery versus 1% with hormone therapy alone.
The regimen cut risk of spread or death by 20% and lowered recurrence risk by 29%.
Johnson & Johnson will seek global approval and said safety matches earlier Erleada studies.